Literature DB >> 21600533

Prevalence and impact of coronary artery disease in patients with pulmonary arterial hypertension.

Avi Shimony1, Mark Jeffrey Eisenberg, Lawrence Glenn Rudski, Robert Schlesinger, Jonathan Afilalo, Dominique Joyal, Leonidas Dragatakis, Andrew Hirsch, Kim Boutet, Benjamin Daniel Fox, David Langleben.   

Abstract

The occurrence and impact of coronary artery disease (CAD) among patients with pulmonary arterial hypertension (PAH) are unknown. We aimed to determine the prevalence, clinical correlates, and effect of CAD in patients with PAH. We reviewed the medical records of consecutive patients diagnosed with PAH at a university-based referral center for pulmonary vascular disease from January 1990 to May 2010. The patients systematically underwent right heart catheterization and coronary angiography as a part of their evaluation. The patients with PAH with CAD (defined as ≥50% stenosis in ≥1 major epicardial coronary artery) were compared to patients without CAD. Among the 162 patients with PAH, the prevalence of CAD was 28.4%. The presence of CAD was associated with older age (66.6 ± 11.5 vs 49.2 ± 14.0 years, p <0.001), systemic hypertension, and dyslipidemia. The patients with PAH and CAD had a lower mean pulmonary arterial pressure (44.6 ± 11.1 vs 49.2 ± 14.0 mm Hg; p = 0.02) than patients without CAD. During a median follow-up of 36 months, 73 patients died. The presence of CAD was a predictor of all-cause mortality on univariate analysis (hazard ratio 1.97, 95% confidence interval 1.21 to 3.20) but not on multivariate analysis, which identified older age (hazard ratio 1.03, 95% confidence interval 1.01 to 1.05) and right atrial pressure (hazard ratio 1.08, 95% confidence interval 1.03 to 1.14) as the only independent predictors. In conclusion, our study has demonstrated that CAD is common among patients with PAH. CAD prevalence increases with age, dyslipidemia, and hypertension, but we did not detect an independent prognostic effect of CAD on mortality.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21600533     DOI: 10.1016/j.amjcard.2011.03.066

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  Pharmacologic stress myocardial perfusion imaging in patients with pulmonary hypertension: What do we know, and what remains to be learned?

Authors:  Andrew Van Tosh; Kenneth J Nichols
Journal:  J Nucl Cardiol       Date:  2018-06       Impact factor: 5.952

2.  Safety of regadenoson stress testing in patients with pulmonary hypertension.

Authors:  Victor M Moles; Thomas Cascino; Ashraf Saleh; Krasimira Mikhova; John J Lazarus; Michael Ghannam; Hong J Yun; Matthew Konerman; Richard L Weinberg; Edward P Ficaro; James R Corbett; Vallerie V McLaughlin; Venkatesh L Murthy
Journal:  J Nucl Cardiol       Date:  2016-11-28       Impact factor: 5.952

Review 3.  Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.

Authors:  Nils P Nickel; Ke Yuan; Peter Dorfmuller; Steeve Provencher; Yen-Chun Lai; Sebastien Bonnet; Eric D Austin; Carl D Koch; Alison Morris; Frédéric Perros; David Montani; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Respir Crit Care Med       Date:  2020-01-15       Impact factor: 21.405

4.  Right ventricular myocardial energetic model for evaluating right heart function in pulmonary arterial hypertension.

Authors:  Jacqueline V Scott; Tanuf U Tembulkar; Meng-Lin Lee; Bradley T Faliks; Kelly L Koch; Anton Vonk-Noordegraaf; Keith E Cook
Journal:  Physiol Rep       Date:  2022-05

5.  Pulmonary arterial hypertension in the elderly-clinical characteristics and long-term survival.

Authors:  Avi Shimony; Benjamin D Fox; Jonathan Afilalo; Lawrence G Rudski; Andrew Hirsch; David Langleben
Journal:  Lung       Date:  2012-10-11       Impact factor: 2.584

6.  Hot topics in the mechanisms of pulmonary arterial hypertension disease: cancer-like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure.

Authors:  Edda Spiekerkoetter; Elena A Goncharova; Christophe Guignabert; Kurt Stenmark; Grazyna Kwapiszewska; Marlene Rabinovitch; Norbert Voelkel; Harm J Bogaard; Brian Graham; Soni S Pullamsetti; Wolfgang M Kuebler
Journal:  Pulm Circ       Date:  2019-11-20       Impact factor: 3.017

Review 7.  Management of cardiovascular risk factors in adults with congenital heart disease.

Authors:  George K Lui; Susan Fernandes; Doff B McElhinney
Journal:  J Am Heart Assoc       Date:  2014-10-30       Impact factor: 5.501

8.  Right ventricular ST-elevation myocardial infarction as a cause of death in idiopathic pulmonary arterial hypertension.

Authors:  Yang Zhan; Barry Burstein; Ali O Abualsaud; Mohamed Nosair; Andrew M Hirsch; Lyda Lesenko; David Langleben
Journal:  Pulm Circ       Date:  2017-05-12       Impact factor: 3.017

9.  Association between a Single Nucleotide Polymorphism in the 3'-UTR of ARHGEF18 and the Risk of Nonidiopathic Pulmonary Arterial Hypertension in Chinese Population.

Authors:  Ding Li; Yan Sun; Xiaochao Kong; Changxing Luan; Youjia Yu; Feng Chen; Peng Chen
Journal:  Dis Markers       Date:  2018-10-14       Impact factor: 3.434

10.  Energy Metabolism in the Failing Right Ventricle: Limitations of Oxygen Delivery and the Creatine Kinase System.

Authors:  Ewan D Fowler; David Hauton; John Boyle; Stuart Egginton; Derek S Steele; Ed White
Journal:  Int J Mol Sci       Date:  2019-04-12       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.